Form 4: ImmuCell Corp Director Acquires 10,000 Stock Options
SEC Form 4 Filing
Bryan K. Gathagan, a director of ImmuCell Corp, acquired 10,000 non-qualified stock options on September 20, 2024.
Summary
- On September 20, 2024, Bryan K. Gathagan, a director of ImmuCell Corp, acquired 10,000 non-qualified stock options.
- The options have an exercise price of $3.60.
- The options are exercisable from September 20, 2027, and expire on September 20, 2029.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative sentiment, but rather provides information about insider activity.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment, as it may signal confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 09/20/2024 | Date of transaction: Director acquired 10,000 non-qualified stock options. |
| 09/20/2027 | Options become exercisable. |
| 09/20/2029 | Options expire. |
| 09/24/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.